Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.

导出 OA

翻译打印收藏纠错

作者： Anne,Derache ^[1] ; Collins C,Iwuji ^[2] ; Kathy,Baisley ^[1] ; Siva,Danaviah ^[3] ; Anne-Geneviève,Marcelin ^[4] ; Vincent,Calvez ^[2] ; Tulio,de Oliveira ^[1] ; François,Dabis ^[2] ; Kholoud,Porter ^[2] ; Deenan,Pillay ^[5]

作者单位： Africa Health Research Institute, Mtubatuba, South Africa. ^[1] Sorbonne University, l'université Pierre et Marie Curie, Institut national de la santé et de la recherche médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique Unité Mixte de Recherche en Santé (IPLESP UMRS 1136), Paris, France. ^[2] Department of Global Health and Infection, Brighton and Sussex Medical School. ^[3] Institute for Global Health, University College London, United Kingdom. ^[4] KwaZulu-Natal Research Innovation and Sequencing Platform, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. ^[5] Université de Bordeaux, Institut de Santé Publique d'Epidémiologie et de Développement, Centre Institut national de la santé et de la recherche médicale 1219, France. ^[6] Division of Infection and Immunity, University College London, United Kingdom. ^[7]

关键词 HIV antiretroviral therapy next-generation sequencing pretreatment drug resistance virological response